geneUp	minExonUp	maxExonUp	geneDown	minExonDown	maxExonDown	source	sourceEvent	sourceUrls	studyNctId	studyTitle	studyAcronym	studyGender	countriesOfStudy	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls
EGFR	1	2	EGFR	8	9	CKB_EVIDENCE	fusion	http						Osimertinib			Lung Cancer	X		A	RESPONSIVE	http,http
EML4			ALK			CKB_EVIDENCE	fusion	http						Crizotinib			Lung Cancer	X		A	RESPONSIVE	http,http
PCM1			JAK2			CKB_TRIAL	fusion	http	NCT1	study1	study1	male	Germany	Ruxolitinib			Leukemia	X		B	RESPONSIVE	http,http